GlassScriptPhysician profile
Scott K Radow
NPI 1356367171
$4,896.93
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,315 · 2020: $521 · 2021: $1,885 · 2022: $1,177.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $802.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $680.11 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $549.70 | 2019-2022 | |
| Grifols USA, LLC | $455.72 | 2019-2022 | |
| Genentech USA, INC. | $422.21 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $344.04 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $174.58 | 2019-2022 | |
| United Therapeutics Corporation | $164.16 | 2019-2022 | |
| Amgen INC. | $142.55 | 2021-2022 | |
| Insmed, INC. | $135.18 | 2019-2022 | |
| Genzyme Corporation | $118.55 | 2021-2022 | |
| Mylan Specialty L.P. | $112.22 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $98.13 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $97.27 | 2019 | |
| Paratek Pharmaceuticals, INC. | $77.55 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $75.22 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.23 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $66.44 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $63.36 | 2019 | |
| Merck Sharp & Dohme LLC | $43.15 | 2019-2020 | |
| Pfizer INC. | $27.57 | 2019-2021 | |
| Philips North America LLC | $25.12 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $24.76 | 2021 | |
| Advanced Respiratory, INC | $24.46 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.94 | 2019 | |
| Baxter Healthcare | $22.09 | 2022 | |
| Nabriva Therapeutics, Plc | $20.33 | 2021 | |
| Vapotherm INC | $19.20 | 2022 | |
| Inogen, INC. | $14.10 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Radow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.